3,711 Shares of Quest Diagnostics Incorporated $DGX Acquired by Sawyer & Company Inc

Sawyer & Company Inc bought a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 3,711 shares of the medical research company’s stock, valued at approximately $865,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Sowell Financial Services LLC raised its position in shares of Quest Diagnostics by 11.3% during the third quarter. Sowell Financial Services LLC now owns 5,360 shares of the medical research company’s stock worth $1,326,000 after acquiring an additional 545 shares during the last quarter. Quadrant Capital Group LLC increased its position in Quest Diagnostics by 51.5% during the 3rd quarter. Quadrant Capital Group LLC now owns 3,477 shares of the medical research company’s stock valued at $810,000 after purchasing an additional 1,182 shares during the period. Pinnacle Associates Ltd. increased its position in Quest Diagnostics by 7.1% during the 3rd quarter. Pinnacle Associates Ltd. now owns 13,633 shares of the medical research company’s stock valued at $3,277,000 after purchasing an additional 900 shares during the period. Nisa Investment Advisors LLC increased its position in Quest Diagnostics by 42.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 23,604 shares of the medical research company’s stock valued at $5,501,000 after purchasing an additional 6,993 shares during the period. Finally, Integrated Advisors Network LLC raised its holdings in Quest Diagnostics by 41.4% during the 3rd quarter. Integrated Advisors Network LLC now owns 1,769 shares of the medical research company’s stock worth $412,000 after purchasing an additional 518 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Insider Activity

In other news, SVP Mark Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total value of $376,288.00. Following the completion of the sale, the senior vice president owned 10,335 shares in the company, valued at $2,430,585.30. The trade was a 13.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Michael Prevoznik sold 22,677 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $243.11, for a total transaction of $5,513,005.47. Following the transaction, the senior vice president owned 37,557 shares in the company, valued at $9,130,482.27. The trade was a 37.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 34,277 shares of company stock worth $8,316,493 in the last quarter. 0.88% of the stock is owned by corporate insiders.

Quest Diagnostics Trading Up 0.2%

NYSE DGX traded up $0.49 during trading hours on Wednesday, hitting $237.62. 338,643 shares of the company’s stock were exchanged, compared to its average volume of 974,698. The stock has a 50-day simple moving average of $237.34 and a 200 day simple moving average of $216.03. Quest Diagnostics Incorporated has a 1-year low of $171.18 and a 1-year high of $248.84. The firm has a market cap of $26.23 billion, a price-to-earnings ratio of 25.25, a PEG ratio of 2.12 and a beta of 0.54. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%. The business had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the previous year, the company posted $2.62 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities analysts forecast that Quest Diagnostics Incorporated will post 11.15 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. The ex-dividend date is Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. Quest Diagnostics’s payout ratio is currently 36.52%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (a-)” rating to a “buy (a)” rating in a research report on Tuesday, October 6th. Mizuho increased their price objective on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Argus set a $260.00 target price on shares of Quest Diagnostics in a research note on Wednesday, July 29th. Barclays lifted their target price on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Finally, Robert W. Baird boosted their target price on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Quest Diagnostics currently has an average rating of “Moderate Buy” and an average target price of $240.58.

Quest Diagnostics Profile

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.